Advertisement

Adolescents with urinary stones have elevated urine levels of inflammatory mediators

  • Kirsten Kusumi
  • John Ketz
  • Vijay Saxena
  • John David Spencer
  • Fayez Safadi
  • Andrew SchwadererEmail author
Original Paper

Abstract

Urinary stones are increasing in children, primarily during adolescence. Although urinary stones are often viewed in the context of intermittent stone events, increasing evidence indicates that stones are a metabolic process associated with chronic kidney disease and cardiovascular disease. These aforementioned stone-associated conditions may have pediatric origins. To compare urine inflammatory markers in otherwise healthy stone forming children versus matched controls. Urine samples were collected from 12 adolescents with urinary stones along with 15 controls. The levels of 30 urine cytokines were measured using a Mesoscale 30-Plex Human Cytokine panel and normalized to urine creatinine levels. Macrophage inflammatory protein 1β and interleukin 13 levels were significantly elevated in the urine of the stone forming adolescents compared to controls. Interleukin 17A was elevated in the urine of controls. This study indicates that urine levels of cytokines involved in chronic inflammation and fibrosis are elevated in urinary stone formers as early as adolescence. Because stone formers are at risk for chronic kidney disease, macrophage inflammatory protein 1β and interleukin 13 represent investigative targets.

Keywords

Innate immunity Cytokine Biomarker Interleukin 

Notes

Funding

This study was funded by intramural funds from The Research Institute at Nationwide Children’s Hospital and Indiana University (Grant no. intramural funds).

Compliance with ethical standards

Conflict of interest

Andrew Schwaderer has received funds for consulting for Allena Pharmaceuticals on a topic unrelated to this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent and (for minors) written informed assent was obtained from all individual participants included in the study.

Supplementary material

240_2019_1133_MOESM1_ESM.pdf (69 kb)
Supplementary file1 (PDF 68 kb)
240_2019_1133_MOESM2_ESM.pdf (51 kb)
Supplementary file2 (PDF 51 kb)

References

  1. 1.
    Tasian GE, Ross ME, Song L, Sas DJ, Keren R, Denburg MR, Chu DI, Copelovitch L, Saigal CS, Furth SL (2016) Annual incidence of nephrolithiasis among children and adults in South Carolina from 1997 to 2012. Clin J Am Soc Nephrol 11(3):488–496.  https://doi.org/10.2215/CJN.07610715 CrossRefGoogle Scholar
  2. 2.
    Matlaga BR, Schaeffer AJ, Novak TE, Trock BJ (2010) Epidemiologic insights into pediatric kidney stone disease. Urol Res 38(6):453–457.  https://doi.org/10.1007/s00240-010-0327-9 CrossRefGoogle Scholar
  3. 3.
    Scales CD, Smith AC, Hanley JM, Saigal CS, Project UDiA (2012) Prevalence of kidney stones in the United States. Eur Urol 62(1):160–165.  https://doi.org/10.1016/j.eururo.2012.03.052 CrossRefGoogle Scholar
  4. 4.
    Anderson L, Mc DJ (1946) The origin, frequency, and significance of microscopic calculi in the kidney. Surg Gynecol Obstet 82:275–282Google Scholar
  5. 5.
    Khan SR (2004) Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 8(2):75–88.  https://doi.org/10.1007/s10157-004-0292-0 CrossRefGoogle Scholar
  6. 6.
    Rule AD, Bergstralh EJ, Melton LJ, Li X, Weaver AL, Lieske JC (2009) Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 4(4):804–811.  https://doi.org/10.2215/CJN.05811108 CrossRefGoogle Scholar
  7. 7.
    Holoch PA, Tracy CR (2011) Antioxidants and self-reported history of kidney stones: the National Health and Nutrition Examination Survey. J Endourol 25(12):1903–1908.  https://doi.org/10.1089/end.2011.0130 CrossRefGoogle Scholar
  8. 8.
    Cappuccio FP, Strazzullo P, Mancini M (1990) Kidney stones and hypertension: population based study of an independent clinical association. BMJ 300(6734):1234–1236CrossRefGoogle Scholar
  9. 9.
    Obligado SH, Goldfarb DS (2008) The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens 21(3):257–264.  https://doi.org/10.1038/ajh.2007.62 CrossRefGoogle Scholar
  10. 10.
    Lieske JC, de la Vega LS, Gettman MT, Slezak JM, Bergstralh EJ, Melton LJ, Leibson CL (2006) Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. Am J Kidney Dis 48(6):897–904.  https://doi.org/10.1053/j.ajkd.2006.09.002 CrossRefGoogle Scholar
  11. 11.
    Jeong IG, Kang T, Bang JK, Park J, Kim W, Hwang SS, Kim HK, Park HK (2011) Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney Dis 58(3):383–388.  https://doi.org/10.1053/j.ajkd.2011.03.021 CrossRefGoogle Scholar
  12. 12.
    Liu Y, Li S, Zeng Z, Wang J, Xie L, Li T, He Y, Qin X, Zhao J (2014) Kidney stones and cardiovascular risk: a meta-analysis of cohort studies. Am J Kidney Dis 64(3):402–410.  https://doi.org/10.1053/j.ajkd.2014.03.017 CrossRefGoogle Scholar
  13. 13.
    Rule AD, Roger VL, Melton LJ, Bergstralh EJ, Li X, Peyser PA, Krambeck AE, Lieske JC (2010) Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol 21(10):1641–1644.  https://doi.org/10.1681/ASN.2010030253 CrossRefGoogle Scholar
  14. 14.
    Scales CD Jr, Tasian GE, Schwaderer AL, Goldfarb DS, Star RA, Kirkali Z (2016) Urinary stone disease: advancing knowledge, patient care, and population health. Clin J Am Soc Nephrol 11(7):1305–1312.  https://doi.org/10.2215/CJN.13251215 CrossRefGoogle Scholar
  15. 15.
    Jang HR, Rabb H (2009) The innate immune response in ischemic acute kidney injury. Clin Immunol 130(1):41–50.  https://doi.org/10.1016/j.clim.2008.08.016 CrossRefGoogle Scholar
  16. 16.
    Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, Muruve D, Shi Y, Munro F, Liapis H, Anders HJ (2013) Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1beta secretion. J Clin Investig 123(1):236–246.  https://doi.org/10.1172/JCI63679 CrossRefGoogle Scholar
  17. 17.
    World Health Organization (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 854:1–452Google Scholar
  18. 18.
    Caudle SE, Katzenstein JM, Karpen SJ, McLin VA (2010) Language and motor skills are impaired in infants with biliary atresia before transplantation. J Pediatr 156(6):936–940.  https://doi.org/10.1016/j.jpeds.2009.12.014 CrossRefGoogle Scholar
  19. 19.
    Khanna M, Sromath D, Mendirata D (2015) The study of obesity in children using fuzzy logic. IJITR 3:1833–1836Google Scholar
  20. 20.
    Watson JR, Hains DS, Cohen DM, Spencer JD, Kline JM, Yin H, Schwaderer AL (2016) Evaluation of novel urinary tract infection biomarkers in children. Pediatr Res 79(6):934–939.  https://doi.org/10.1038/pr.2016.33 CrossRefGoogle Scholar
  21. 21.
    Mulay SR, Evan A, Anders HJ (2014) Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transplant 29(3):507–514.  https://doi.org/10.1093/ndt/gft248 CrossRefGoogle Scholar
  22. 22.
    Khan SR (2013) Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol 189(3):803–811.  https://doi.org/10.1016/j.juro.2012.05.078 CrossRefGoogle Scholar
  23. 23.
    Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, Muruve D, Shi Y, Munro F, Liapis H, Anders HJ (2013) Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Investig 123(1):236–246.  https://doi.org/10.1172/JCI63679 CrossRefGoogle Scholar
  24. 24.
    Allen SJ, Crown SE, Handel TM (2007) Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25:787–820.  https://doi.org/10.1146/annurev.immunol.24.021605.090529 CrossRefGoogle Scholar
  25. 25.
    Menten P, Wuyts A, Van Damme J (2002) Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 13(6):455–481CrossRefGoogle Scholar
  26. 26.
    Maurer M, von Stebut E (2004) Macrophage inflammatory protein-1. Int J Biochem Cell Biol 36(10):1882–1886.  https://doi.org/10.1016/j.biocel.2003.10.019 CrossRefGoogle Scholar
  27. 27.
    Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG (2001) B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2(12):1126–1132.  https://doi.org/10.1038/ni735 CrossRefGoogle Scholar
  28. 28.
    Kusmartsev S, Dominguez-Gutierrez PR, Canales BK, Bird VG, Vieweg J, Khan SR (2016) Calcium oxalate stone fragment and crystal phagocytosis by human macrophages. J Urol 195(4 Pt 1):1143–1151.  https://doi.org/10.1016/j.juro.2015.11.048 CrossRefGoogle Scholar
  29. 29.
    de Vries JE, Zurawski G (1995) Immunoregulatory properties of IL-13: its potential role in atopic disease. Int Arch Allergy Immunol 106(3):175–179.  https://doi.org/10.1159/000236842 CrossRefGoogle Scholar
  30. 30.
    Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B (1993) Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362(6417):248–250.  https://doi.org/10.1038/362248a0 CrossRefGoogle Scholar
  31. 31.
    Seyfizadeh N, Gharibi T, Babaloo Z (2015) Interleukin-13 as an important cytokine: a review on its roles in some human diseases. Acta Microbiol Immunol Hung 62(4):341–378.  https://doi.org/10.1556/030.62.2015.4.2 CrossRefGoogle Scholar
  32. 32.
    Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, McKerrow JH, Wakefield LM, Letterio JJ, Wynn TA (2004) IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 173(6):4020–4029CrossRefGoogle Scholar
  33. 33.
    Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA (1999) Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Investig 103(6):779–788.  https://doi.org/10.1172/JCI5909 CrossRefGoogle Scholar
  34. 34.
    Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G (1993) Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362(6417):245–248.  https://doi.org/10.1038/362245a0 CrossRefGoogle Scholar
  35. 35.
    Jain-Vora S, Wert SE, Temann UA, Rankin JA, Whitsett JA (1997) Interleukin-4 alters epithelial cell differentiation and surfactant homeostasis in the postnatal mouse lung. Am J Respir Cell Mol Biol 17(5):541–551.  https://doi.org/10.1165/ajrcmb.17.5.2883 CrossRefGoogle Scholar
  36. 36.
    Huaux F, Liu T, McGarry B, Ullenbruch M, Phan SH (2003) Dual roles of IL-4 in lung injury and fibrosis. J Immunol 170(4):2083–2092CrossRefGoogle Scholar
  37. 37.
    Singh RR, Saxena V, Zang S, Li L, Finkelman FD, Witte DP, Jacob CO (2003) Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 170(9):4818–4825CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Akron Children’s HospitalNortheast Ohio Medical UniversityAkronUSA
  2. 2.Center for Clinical and Translational ResearchThe Research Institute at Nationwide Children’s HospitalColombusUSA
  3. 3.Division of Nephrology, Department of PediatricsIndiana UniversityBloomingtonUSA
  4. 4.Riley Physicians Kidney DiseasesIndianapolisUSA

Personalised recommendations